Technology Innovation Institute’s Directed Energy Research Centre becomes First-in-Region to Replicate Electromagnetic Pulses from High-altitude Nuclear Reaction
Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) today announced that its Directed Energy Research Centre (DERC) has become the first such entity in the region capable of reproducing the high-altitude electromagnetic pulses (HEMP) generated during nuclear reaction in high altitudes at its electromagnetic compatibility (EMC) labs. The Nuclear Electromagnetic Pulse Simulator offers critical infrastructures, service providers, and research institutions in the UAE and wider GCC region greater autonomy when it comes to testing - a function that needed to earlier be outsourced abroad.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005404/en/
Dr. Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (Photo: AETOSWire)
DERC’s EMC labs comprise a modular semi-anechoic chamber that enables testing to evaluate susceptibility of electronics to electromagnetic pulses while providing the necessary evidence that these comply with international standards.
In partnership with Montena Technologies, a leading Switzerland-based company specialising in the generation and measurement of high-voltage fast transient impulses, simulating natural and human-made electromagnetic phenomena, and a key manufacturer of Nuclear EMP systems, DERC has commissioned a system to replicate the electromagnetic environment generated by a nuclear reaction at high altitudes (more than 40 km above the ground) in the laboratory.
Speaking on the development, Dr. Ray O. Johnson, CEO of Technology Innovation Institute (TII), said: “In line with our ambition to continue to develop breakthrough solutions that drive IP development and facilitate cutting-edge scientific research, this new capability is important. As a leading technology institute in the region, we are committed to building the UAE’s science, technology, and engineering prowess, while leveraging the power of advanced technologies to make our world more secure.”
Dr Chaouki Kasmi, Chief Researcher, Directed Energy Research Centre (DERC), said: “We are delighted to add this capability to DERC’s growing resources of cutting-edge technological solutions that are shaping our future. A Nuclear Electromagnetic Pulse simulator is unique to the GCC region and is crucial for the protection of strategic systems and critical infrastructures.”
DERC and TII can now offer government entities and industry in the UAE, the requisite experimental, numerical, and analytical support to verify accurate hardening of equipment against multiple international standards.
Manufacturers keen to export their products to markets compliant with EMC directives (namely the EU or the United States) and those conforming to IEC requirements on HEMP protection will appreciate the significance of this announcement.
For his part, Werner Hirschi, CEO, Montena Technologies SA, said: “As a global leader in providing equipment for simulation of electromagnetic threats, for the measurement of pulsed electromagnetic quantities and for the transmission of fast pulsed signals in noisy environments, we are pleased to partner with DERC in implementing a unique infrastructure that will trigger the impulse to success. Montena looks forward to a long and fruitful collaboration with TII and is committed to supporting TII in meeting its goal of creating innovation for a better world.”
For more information, visit
www.tii.ae
Connect with us on social media:
LinkedIn:
https://www.linkedin.com/company/tiiuae/
Twitter:
https://twitter.com/TIIuae
Instagram:
https://www.instagram.com/tiiuae/
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211018005404/en/
Contact information
Technology Innovation Institute
Hanz Valbuena
comms@atrc.ae
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom